Atopic dermatitis (AD) is considered as a chronic inflammatory, pruritic and relapsing skin disease that is commonly associated with other atopic comorbidities (1). AD affects ~8% of the world populations with a reported prevalence ranges from ~10% of adults and ~20% of the paediatric population in developed countries (2-3). Complex pathophysiologi­cal mechanism of AD involves environmental, immune system and genetics factors. Role of microorganism has been suggested in the regulation of various biological processes in human body and human microbiome is considered as one of the human organ as they harbour organ specific niche in human body. Considering the diversity and organ-specific niches of the human microbiome, lesser is known about beneficial microbiota. However, with the introduction of high-throughput sequencing technology, understanding of Gut and skin microbiome has been significantly improved and their association with human disease pathogenesis is established including skin diseases like AD. The diagnostic of AD is based on clinical symptoms, whereas the SCORing for Atopic Dermatitis index (SCORAD) helps physicians to assess disease severity on a regular basis (4, 5). Mild to moderate cases are usually treated with emollients, topical steroids and phototherapy. In severe cases, oral corticosteroids and other systemic immunosup­pressants, including cyclosporine, methotrexate sodium or azathioprine sodium, may be required (6). The use of mon­oclonal antibodies and Janus kinase inhibitors has shown promising results in terms of both efficacy and safety (7). Several studies have demonstrated that immunological tolerance is closely related to the composition of intestinal microbiota (8). One of these functions is a contribution to the degradation of complex indigestible pol­ysaccharides and an essential role in the production of cer­tain nutrients. Furthermore, short-chain fatty acids (SCFAs) resulting from fermentation of dietary fibre by bacteria in the gastrointestinal tract play a protective role against bacterial translocation from the intestinal lumen. Those patients whose intestinal microbiota is rich in SCFA-producing bacteria have a lower tendency to suffer bacterial translocation from the gut (9) and a negative correlation was observed with disease severity. Indeed, this phenomenon may be partly responsible for the interconnection between the intes­tinal and skin microbiota and may modulate the immune and metabolic response of the skin, which would affect the microbial composition of the skin itself (10). Substantial evidences indicated the association between microbial dysbiosis and development of allergic disease conditions (11) and there are various factors reported to influence the gut and skin microbial homeostasis for e.g. mode of delivery (C-section vs normal vaginal delivery), the type of feeding, antibiotic use, diet (breast milk vs children fed with formula or in a mixed manner (12). Probiotics are described as “live microorganisms which when administered in adequate amounts confer health benefits to the host,” the definition is given with the agreement of the World Health Organization (WHO) and the Food and Agriculture Organization (United Nations) (13). Despite extensive research, only a few bacterial strains have proven their potential in terms of safety and efficacy e.g. Bifidobacterium and Lactobacillus species. There are various clinical trials performed to prove the safety and efficacy of probiotics in Atopic dermatitis but contradictory findings reported that warrant the further investigations (14-19). The contradictory findings may be attributed to various factors such as different populations, different probiotic formulation, targeting different age groups, duration of probiotic consumption and follow up durations. Considering the above mentioned facts further randomized clinical trial based investigation is highly warranted to assess the efficacy of the probiotics in AD. Therefore, the aim of the present study is to perform a randomized double-blind placebo controlled trial to compare efficacy of probiotic formulation (developed by Unique Biotech, FSSAI approved nutraceuticals) in Indian patients with Atopic Dermatitis in paediatric population with age group of two to 18 years by assessing the SCORAD index and status of inflammatory cytokines. The probiotic formulation (i.e. One gram sachet containing five Billion colony forming units (CFU) of Lactobacillus johnsonii UBLJ (01-3.8 billion CFU), Bifidobacterium breve UBBr (01-0.6 billion CFU), Lactobacillus fermentum UBLF (31-0.3 billion CFU), Lactobacillus reuteri UBLRu (87-0.3 billion CFU) along with Vitamin D3 (cholecalciferol, 400 IU), Vitamin E (d-alpha tocopherol, 4mg/6 IU, Fructooligosaccharide (100 mg).

References:

1.      Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. (2020) 156:44–56. doi: 10.1001/jamadermatol.2019.3336

2.      Garg N, Silverberg JI. Epidemiology of childhood atopic dermati­tis. Clin Dermatol 2015; 33:281–8.

3.      Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345–60. 

4.      Eichenfield LF, Boguniewicz M, Simpson EL, Russell JJ, Block JK, Feldman SR, et al. Translating atopic dermatitis management guidelines into practice for primary care providers. Pediatrics. (2015) 136:554-65. doi: 10.1542/peds.2014-3678.

5.      Antunes AA, Solé D, Carvalho VO, Bau AEK, Kuschnir FC,MalloziMC, et al. Updated practical guide on atopic dermatitis - Part I: etiopathogenesis, clinical features, and diagnosis. joint position paper of the Brazilian association of allergy and immunology and the Brazilian society of pediatrics. Arq Asma Alerg Imunol. (2017) 1:131–56. doi: 10.5935/2526-5393.20170019.

6.      Sedeh FB, Henning MAS, Jemec GBE, Ibler KS. Comparative efficacy and safety of monoclonal antibodies and Janus kinase inhibitors in moderate-to-severe atopic dermatitis: a system­atic review and meta-analysis. Acta Derm Venereol 2022; 24:adv00764.

7.      Wollenberg A, Kinberger M, Arents B et al. European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. J Eur Acad Dermatol Venereol 2022; 36:1409–31.

8.      Awasthi S,Wilken R, Patel F, German JB, Mills DA, Lebrilla CB, et al. Dietary supplementation with Bifidobacterium longum subsp. infantis (B infantis) in healthy breastfed infants: study protocol for a randomised controlled trial. Trials. (2016) 17:340. doi: 10.1186/s13063-016-1467-1

9.      Plöger S, Stumpff F, Penner GB et al. Microbial butyrate and its role for barrier function in the gastrointestinal tract. Ann N Y Acad Sci 2012; 1258:52–9.

10.  Sümegi A, Szegedi A, Gál M et al. Analysis of components of the CD14/TLR system on leukocytes of patients with atopic dermati­tis. Int Arch Allergy Immunol 2007; 143:177–84.

11.  Dzidic M, Abrahamsson TR, Artacho A, Collado MC, Mira A, Jenmalm MC. Oral microbiota maturation during the first 7 years of life in relation to allergy development. Allergy. (2018) 73:2000–11. doi: 10.1111/all.13449

12.  Milani C, Duranti S, Bottacini F, Casey E, Turroni F, Mahony J, et al. The first microbial colonizers of the human gut: composition, activities, and health implications of the infant gut microbiota. Microbiol Mol Biol Rev. (2017) 81:e00036–17. doi: 10.1128/MMBR.00036-17

13.  Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al., 2014. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11 (8), 506e514.

14.  Feíto-Rodríguez M, Ramírez-Boscà A, Vidal-Asensi S. Randomized double-blind placebo-controlled clinical trial to evaluate the effect of a mixture of probiotic strains on symptom severity and use of corticosteroids in children and adolescents with atopic dermatitis. Clin Exp Dermatol. 2023;48(5):495-503.

15.  Wickens K, Black P, Stanley TV et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy 2012; 42:1071–9.

16.  Matsumoto M, Aranami A, Ishige A et al. LKM512 yogurt con­sumption improves the intestinal environment and induces the T-helper type 1 cytokine in adult patients with intractable atopic dermatitis. Clin Exp Allergy 2007; 37:358–70.

17.  Woo SI, Kim JY, Lee YJ et al. Effect of Lactobacillus sakei supple­mentation in children with atopic eczema-dermatitis syndrome. Ann Allergy Asthma Immunol 2010; 104:343–8.

18.  Nocerino R, Bedogni G, Carucci L et al. The impact of formula choice for the management of pediatric cow’s milk allergy on the occurrence of other allergic manifestations: the atopic march cohort Study. J Pediatr 2021; 232:183–91.e3.

19.  Rather IA, Kim BC, Lew LC et al. Oral administration of live and dead cells of Lactobacillus sakei proBio65 alleviated atopic der­matitis in children and adolescents: a randomized, double-blind, and placebo-controlled study. Probiotics Antimicrob Proteins 2021; 13:315–26.